Somatotropin
- Generic Name
- Somatotropin
- Brand Names
- Genotropin, Humatrope, Norditropin, Norditropin Nordiflex, Nutropin, Nutropinaq, Omnitrope, Saizen, Serostim, Zomacton, Zorbtive, NutropinAq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 12629-01-5
- Unique Ingredient Identifier
- NQX9KB6PCL
- Background
Human growth hormone (HGH), also known as somatotropin, is a peptide hormone that is synthesized and secreted by the somatotropic cells of the anterior pituitary gland. Growth hormone plays an essential role in growth regulation during childhood as well as other basal metabolic functions, muscle and fat mass regulation, blood glucose level regulation, and li...
- Indication
Somatotropin is indicated for the treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone, short stature associated with Turner syndrome, Prader-Willi syndrome (PWS), idiopathic short stature (ISS), short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency, and shor...
- Associated Conditions
- Adult Onset Growth Hormone Deficiency, Cachexia, Childhood-onset Growth Hormone Deficiency, Growth Failure, HIV Wasting Syndrome, Short Bowel Syndrome (SBS), Short Stature
- Associated Therapies
- -
Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 86
- Registration Number
- NCT00184730
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Growth Hormone Treatment in Infants Aged 1 to 2 Years With Chronic Renal Insufficiency (CRI) and Growth Retardation.
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 16
- Registration Number
- NCT00184769
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Zaragoza, Spain
HORMA: Hormonal Regulators of Muscle and Metabolism in Aging
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2009-06-02
- Lead Sponsor
- National Institute on Aging (NIA)
- Target Recruit Count
- 108
- Registration Number
- NCT00183040
- Locations
- 🇺🇸
Tufts University, Boston, Massachusetts, United States
🇺🇸Washington University School of Medicine, St. Louis, Missouri, United States
Growth Hormone Treatment in Adult Patients With Chronic Kidney Disease
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 140
- Registration Number
- NCT00184652
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom
Prevention of Growth Retardation by Early Treatment With Growth Hormone (GH) in Children With CJA Treated by Corticosteroid Therapy
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 21
- Registration Number
- NCT00174291
- Locations
- 🇫🇷
Pfizer Investigational Site, Paris, France
Treatment With Recombinant Human Growth Hormone (GH) in Children With Short Stature Secondary to a Long Term Corticoid Therapy
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00174187
- Locations
- 🇫🇷
Pfizer Investigational Site, Paris, France
Evaluation of the Efficacy and Safety of Recombinant Human Growth Hormone (rhGH) in the Treatment of Children With Short Bowel Syndrome
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-10-31
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 14
- Registration Number
- NCT00169637
- Locations
- 🇫🇷
Alain LACHAUX, Lyon, France
Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-08-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT00174278
- Locations
- 🇫🇷
Pfizer Investigational Site, Paris, France
Somatropin Therapy In Children Born Preterm But Appropriate For Gestational Age
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 33
- Registration Number
- NCT00174460
- Locations
- 🇩🇪
Pfizer Investigational Site, Tuebingen, Germany
Growth Retardation In Children With Special Pathological Conditions Or Disease
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2012-12-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 46
- Registration Number
- NCT00163215
- Locations
- 🇫🇷
Pfizer Investigational Site, Vandoeuvre Les Nancy Cedex, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.